Please be aware the U.S. Food and Drug Administration (FDA) has informed the public that use of the diabetes medication Actos (Pioglitazone) for more than one year may be associated with an increased risk of bladder cancer.
According to the article you posted: the application of Pioglitazone to DRG neurons did not significantly alter the anterograde and retrograde transport of lysosomes within unmyelinated axons. Pioglitazone halts axonal degeneration in a mouse model of X-linked adrenoleukodystrophy. It appears there are no human studies as of yet. Maybe they will establish a Clinical Trial soon?
Viewing 3 reply threads
You must be logged in to reply to this topic.
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.